In Vivo and In Vitro Pharmacology Studies
Advance your pharmacological research with support from Charles River. Combining expertise in numerous therapeutic areas with expansive knowledge of molecules, modalities, and model systems, our team has created a broad portfolio of in vitro and in vivo study models across many disease indications to support your pharmacology testing and deepen understanding of your novel therapy.
Built on a deep foundation of chemistry and disease biology, our comprehensive support for your cardiovascular and metabolic disease drug discovery includes innovative target identification and validation platforms and complex in vitro and in vivo pharmacology studies.
Improve your understanding of disease, host interactions, and treatment effects. Using a suite of methods and models, our infectious disease specialists can help you assess your novel anti-infectives like antimicrobials, antivirals, and vaccines.
Even therapeutics that don’t target the immune system may be affected by its mechanisms. Eliminate the risks and deepen your understanding with help from our dedicated immunology experts.
Get comprehensive support from our team of musculoskeletal researchers, veterinarians, pathologists, and surgeons who are experienced in the evaluation of bone and cartilage drug efficacy, musculoskeletal tissue healing and biocompatibility, orthopedic device efficacy, and the effects of new orthobiologic applications.
Enter the new era of CNS drug discovery with robust, reproducible models validated for multiple assay platforms and reliable tools to screen small molecules through biologics. Our team of neuroscientists continues to establish the most relevant in vitro and in vivo models and assays of acute and chronic neurological diseases to help you identify and test new compounds in this challenging field.
From early discovery to safety assessment, we have the tools and experience to develop your ocular therapeutics with cost-effective efficiency. Achieve more definitive proof-of-concept and robust non-GLP screening with our validated disease models, and optimize study model design and management with help from our team.
Speed entrance to the clinic with translational oncology study models that mirror human cancers. Interrogate every aspect of the tumor microenvironment or test your therapy’s effects in studies that employ real patient tissue with our diverse collection of in vitro assays and in vivo pharmacology models.
Collect disease-relevant data despite low patient populations. Using CRISPR and stem cell technology to mimic specific diseases, our scientists employ tools like high-throughput screening (HTS), cell-based assays, and research study models to derive safety data that translates to the clinic.
Cover all your bases. Spanning numerous disease indications, our in vivo pharmacology models of respiratory disease are enhanced with the most appropriate model and translational biomarkers to create a study that satisfies the needs of your compound and discovery program.
Neuroscience Digital Education
Learn more about our neuroscience portfolio by browsing our CNS digital education resources. Look through relevant webinars, videos, and other resources.
Browse Our Resources
Still have questions for our scientists?
Frequently Asked Questions (FAQs) about In Vivo Pharmacology Studies
What is in vivo pharmacology?
In vivo pharmacology is the study of the biological effects of a drug in a complex living organism and is used to observe the complex physiological effects of a drug. In vivo Pharmacology studies can help researchers understand how a compound might treat a specific disease area.
What disease areas can be researched with in vitro and in vivo studies?
Charles River offers early research and proof-of-principle pharmacology studies in relevant cell and animal models of human diseases to assist your efficacy evaluations. We have experience in multiple disease areas. Our scientists are experts in the fields of Neuroscience, Oncology, Immuno-Oncology, Infectious Disease, Inflammation, Autoimmune Disease, Rare Disease, Respiratory Disease, Ocular Disease, Musculoskeletal Disease, and Cardiovascular/Metabolic Disease.